Trump Action Archive

Supporting reports

• CDC blocked publication of report demonstrating COVID-19 vaccine efficacy — The Centers for Disease Control and Prevention blocked publication of a scientific report in its own journal showing the efficacy of the COVID-19 vaccine, according to reporting by The Washington Post. The blocked report found that the COVID-19 vaccine reduced hospitalizations and emergency room visits among healthy adults during winter 2025–2026. The suppression of peer-reviewed vaccine efficacy data represents a departure from standard scientific publication practices and raises questions about political interference in public health communication.

Supporting reports

• Trump signed Executive Order 14401 accelerating FDA review and access to psychedelic drugs for serious mental illness treatment. — President Trump signed Executive Order 14401 on April 18, 2026, directing federal agencies to accelerate research, clinical trials, and FDA approval pathways for psychedelic drugs (including ibogaine) to treat serious mental illnesses and reduce suicide rates. The order allocates $50 million from HHS existing funds for state-federal collaboration, establishes Right to Try access for eligible patients, directs the Attorney General to expedite rescheduling of Schedule I substances that complete Phase 3 trials, and mandates data-sharing between HHS, FDA, VA, and private sector partners. The order cites a 37 percent increase in suicide rates from 2000–2018 and notes veteran suicide rates are twice the general population.
• Trump administration issues executive order to accelerate psychedelic medication access — On 18 April 2026, the Trump administration signed an executive order directing federal agencies to accelerate access to psychedelic medications for people with serious mental illnesses. The order mandates inter-agency collaboration between the Department of Veterans Affairs and other agencies to share data and increase clinical trial participation, and directs the Drug Enforcement Administration to reschedule psychedelics that complete FDA approval. Legal experts characterize the order's concrete legal impact as minimal, though its symbolic value—reinforced by a high-profile press conference featuring podcaster Joe Rogan and former Navy SEAL Marcus Luttrell—may influence policy direction and signal Republican openness to psychedelic research.
• Trump issues executive order accelerating psychedelic drug approvals for serious mental illness treatment — President Trump signed an executive order on April 18, 2026, directing federal agencies to accelerate approval pathways for psychedelic drugs (including ibogaine compounds) to treat serious mental illnesses. The order mandates FDA prioritization of Breakthrough Therapy-designated psychedelics, establishes Right to Try access for eligible patients, allocates $50 million in HHS funding for state-federal collaboration, and directs the Attorney General to expedite rescheduling of Schedule I substances that complete Phase 3 clinical trials. The order targets treatment gaps for patients unresponsive to standard therapies, particularly veterans with high suicide rates.
• White House issued fact sheet on executive order accelerating psychedelic drug treatments for serious mental illness — The White House published a fact sheet on April 18, 2026, describing an executive order signed by President Trump directing the FDA to issue Commissioner's National Priority Vouchers for psychedelic drugs with Breakthrough Therapy designations, establishing a Right to Try pathway for investigational psychedelics, allocating $50 million through ARPA-H for state-matched psychedelic research, and directing the Attorney General to initiate rescheduling reviews upon Phase 3 trial completion. The fact sheet frames the order as addressing mental illness and veteran suicide rates.
• White House signed executive order accelerating psychedelic drug approvals for serious mental illness — President Trump signed Executive Order 14401 directing the FDA to prioritize review of psychedelic drugs (including ibogaine) with Breakthrough Therapy designation, allocate $50 million to state-federal collaboration programs, establish Right to Try pathways for eligible patients, facilitate data-sharing between HHS, FDA, and the Department of Veterans Affairs, and direct the Attorney General to expedite rescheduling of Schedule I substances that complete Phase 3 trials for approved mental health treatments.
• President Trump signed executive order accelerating psychedelic drug research and access for mental health treatment — On April 20, 2026, President Trump signed an executive order directing federal agencies to accelerate research into and improve access to psychedelic drugs—particularly ibogaine and psilocybin—as treatments for serious mental illnesses, with emphasis on veterans suffering from PTSD, treatment-resistant depression, and suicide risk. The order directs HHS, FDA, DOJ, and VA to collaborate on clinical trials, regulatory pathways, Right to Try expansions, and rescheduling considerations. The White House states the order includes $50 million in federal funding for ibogaine research and aims to reduce barriers that have forced veterans to seek treatment outside the United States.
• Rep. Auchincloss questioned FDA approval of psychedelics as political appeasement — During RFK Jr.'s budget hearing, Rep. Auchincloss questioned whether Trump granted FDA approval for psychedelics to appease Joe Rogan and shore up support from his base amid the disastrous Iran war. Auchincloss stated: "In order to appease Rogan's ire, he grants FDA approval" and argued that "safety and efficacy should be the standards by which psychedelics are approved, not the president's attempt to shore up support from his base for a disastrous war in Iran."